- Trials with a EudraCT protocol (410)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
410 result(s) found for: Lymphocyte Count.
Displaying page 1 of 21.
EudraCT Number: 2021-006055-33 | Sponsor Protocol Number: HypoGI | Start Date*: 2023-03-05 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Assessing the feasibility of pharmacologically induced hypothyroidism in patients with advanced pancreatic cancer - a pilot study | ||
Medical condition: Patients with newly diagnosed metastatic pancreatic cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-002405-47 | Sponsor Protocol Number: The CogNaive Study | Start Date*: 2007-07-31 |
Sponsor Name:Imperial College | ||
Full Title: A randomised prospective study assessing changes in neuro-cognitive function, using a computerised test battery, in treatment naïve HIV-1 positive subjects commencing two different antiretroviral r... | ||
Medical condition: HIV | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-000381-20 | Sponsor Protocol Number: 27820 | Start Date*: 2007-11-16 | |||||||||||
Sponsor Name:Merck Serono S.A. - Geneva | |||||||||||||
Full Title: A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple... | |||||||||||||
Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) FR (Completed) GB (Completed) CZ (Completed) BE (Completed) EE (Completed) AT (Completed) PT (Completed) NL (Completed) DE (Completed) DK (Completed) IT (Completed) GR (Completed) LV (Completed) LT (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003977-93 | Sponsor Protocol Number: 87RI-0015 | Start Date*: 2019-03-27 |
Sponsor Name:RevImmune | ||
Full Title: International, multicenter, randomized, double-blinded, placebo-controlled study of Recombinant Interleukin-7 (CYT107) to restore absolute lymphocyte counts (ALC) in patients with Sepsis | ||
Medical condition: Sepsis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004849-26 | Sponsor Protocol Number: Parachute04 | Start Date*: 2015-02-05 | ||||||||||||||||
Sponsor Name:UMC Utrecht | ||||||||||||||||||
Full Title: PARACHUTE-trial Prospective Analysis of an individualized dosing Regimen of ATG (Thymoglobulin) in Children Undergoing HCT: redUcing Toxicity and improving Efficacy – a single arm phase II study | ||||||||||||||||||
Medical condition: Leukemia and immunedeficiency syndromes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-001443-19 | Sponsor Protocol Number: AC-058A200 | Start Date*: 2008-11-26 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd | |||||||||||||
Full Title: Multicenter, randomized, double-blind, placebo-controlled, Phase IIa study to evaluate the efficacy, safety, and tolerability of ACT-128800, an S1P1 receptor agonist, administered for 6 weeks to su... | |||||||||||||
Medical condition: Moderate to severe chronic plaque psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) HU (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002497-27 | Sponsor Protocol Number: KFJ-2020-01_IMUNOR | Start Date*: 2020-10-27 |
Sponsor Name:Thomayerova nemocnice | ||
Full Title: A randomized, open-label, phase IV monocentric study evaluating the clinical effect of oral immunomodulatory therapy with IMUNOR® in patients with moderate COVID-19 disease | ||
Medical condition: Patients with COVID -19 disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001028-16 | Sponsor Protocol Number: EARLY-DEX | Start Date*: 2021-05-21 |
Sponsor Name:Fundación para la Investigación e Innovación Biomédica (FIIB) del Hospital Universitario Infanta Leonor y Hospital Unive | ||
Full Title: DEXamethasone EARLY administration in hospitalized patients with Covid-19 pneumonia and high risk of developing acute respiratory distress syndrome | ||
Medical condition: Hospitalized patients with Covid-19 pneumonia who do not require oxygen therapy on admission associated with at least two of the three following factors related with severe Covid-19: lactate dehydr... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000417-16 | Sponsor Protocol Number: Uni-Köln-4480 | Start Date*: 2021-10-20 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: A Phase I / randomized Phase II trial to analyse safety and efficacy of human SARS-CoV 2 specific T lymphocyte transfer in patients with COVID-19 in need of treatment or at risk of severe COVID-19 | |||||||||||||
Medical condition: Patients who are tested positive for SARS-CoV-2 by PCR from upper or lower respiratory sites and are at increased risk for developing critical disease presenting with moderate disease -WHO ordinal ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002155-11 | Sponsor Protocol Number: B5411003 | Start Date*: 2021-06-09 |
Sponsor Name:Pfizer Inc. | ||
Full Title: A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO ACCESS THE EFFICACY AND SAFETY OF PF-06462700 ADMINISTERED INTRAVENOUSLY AT 40 MG/KG/DAY FOR 4 DAYS IN JAPANESE PARTICIPANTS WITH MODERATE AND ABOVE A... | ||
Medical condition: Moderate and above aplastic anemia | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2006-000741-19 | Sponsor Protocol Number: Fl SC ale (Full-Scale) | Start Date*: 2007-07-04 |
Sponsor Name:UHL NHS Trust | ||
Full Title: A phase I study of subcutaneous alemtuzumab in combination with oral fludarabine in previously untreated patients with chronic lymphocytic leukaemia. | ||
Medical condition: Chronic Lymphocytic Leukaemia (CLL) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2004-004727-36 | Sponsor Protocol Number: NR 8230-3/2004 | Start Date*: 2005-02-10 |
Sponsor Name:Charles University, 3rd Faculty of Medicine | ||
Full Title: Influence of low-dose i.v. growth hormone treatment together with glutamine supplementation in late-phase critically ill patient after multiple injury. A pilot study. | ||
Medical condition: Prolonged phase of critical illness after severe multiple trauma | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-003056-36 | Sponsor Protocol Number: CBAF312A2304 | Start Date*: 2012-10-31 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary pro... | |||||||||||||
Medical condition: Secondary progressive multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Ongoing) IE (Completed) DE (Prematurely Ended) CZ (Completed) SK (Completed) NL (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) AT (Completed) SE (Completed) PT (Prematurely Ended) IT (Prematurely Ended) LV (Completed) GR (Completed) LT (Ongoing) EE (Completed) BE (Prematurely Ended) PL (Completed) BG (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001490-95 | Sponsor Protocol Number: ESPRIT 002: STALWART | Start Date*: 2006-04-21 |
Sponsor Name:National Institute of Allergy and Infectious Diseases (NIAID) | ||
Full Title: A Randomized, Open-Label, International Study of Subcutaneous Recombinant Interleukin-2 (rIL-2, Aldesleukin) with and without Concomitant Antiretroviral Therapy in Patients with HIV-1 Infection and... | ||
Medical condition: HIV infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) ES (Completed) PT (Completed) DE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-001366-42 | Sponsor Protocol Number: BGB-3111-305 | Start Date*: 2018-11-07 | ||||||||||||||||
Sponsor Name:BeiGene, Ltd. | ||||||||||||||||||
Full Title: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | ||||||||||||||||||
Medical condition: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) ES (Completed) BE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) SE (Completed) NL (Completed) IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003131-31 | Sponsor Protocol Number: M19-956 | Start Date*: 2020-02-05 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Phase 2a, Double-Blind, Randomized, Placebo-Controlled Study of Ravagalimab in Subjects with Moderately to Severely Active Primary Sjogren’s Syndrome. | |||||||||||||
Medical condition: Moderately to Severely Active Primary Sjogren's Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001110-38 | Sponsor Protocol Number: TOCIVID-19 | Start Date*: 2020-03-18 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE "G. PASCALE" | |||||||||||||
Full Title: Multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia | |||||||||||||
Medical condition: COVID-19 pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005553-39 | Sponsor Protocol Number: 1501 | Start Date*: 2015-12-29 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: Effects of Sativex on blood leukocytes in patients with lymphoma/chronic lymphocytic leukaemia | ||
Medical condition: Lymphoma and chronic lymphocytic leukaemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004808-60 | Sponsor Protocol Number: HD-CAR-1/V04 | Start Date*: 2018-04-12 | ||||||||||||||||
Sponsor Name:University Hospital Heidelberg | ||||||||||||||||||
Full Title: Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - A unicenter Phase I /II clinical trial | ||||||||||||||||||
Medical condition: Relapsed and/or refractory CD19+ leukemia and lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004429-15 | Sponsor Protocol Number: GEM-1402 | Start Date*: 2016-02-16 | |||||||||||
Sponsor Name:GRUPO ESPAÑOL MULTICISPLINAR DE MELANOMA | |||||||||||||
Full Title: Phase II multicente, non randomized, open label trial of nivolumab in combination with ipilimumab in subjects with previously untreated metastatic uveal melanoma. | |||||||||||||
Medical condition: Metastatic uveal melanoma non suitable for radical resection. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.